↓ Skip to main content

Immunosuppressive drugs and fertility

Overview of attention for article published in Orphanet Journal of Rare Diseases, October 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
5 news outlets
blogs
1 blog
twitter
13 X users
facebook
2 Facebook pages

Citations

dimensions_citation
138 Dimensions

Readers on

mendeley
201 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Immunosuppressive drugs and fertility
Published in
Orphanet Journal of Rare Diseases, October 2015
DOI 10.1186/s13023-015-0332-8
Pubmed ID
Authors

Clara Leroy, Jean-Marc Rigot, Maryse Leroy, Christine Decanter, Kristell Le Mapihan, Anne-Sophie Parent, Anne-Claire Le Guillou, Ibrahim Yakoub-Agha, Sébastien Dharancy, Christian Noel, Marie-Christine Vantyghem

Abstract

Immunosuppressive drugs are used in the treatment of inflammatory and autoimmune diseases, as well as in transplantation. Frequently prescribed in young people, these treatments may have deleterious effects on fertility, pregnancy outcomes and the unborn child. This review aims to summarize the main gonadal side effects of immunosuppressants, to detail the effects on fertility and pregnancy of each class of drug, and to provide recommendations on the management of patients who are seen prior to starting or who are already receiving immunosuppressive treatment, allowing them in due course to bear children. The recommendations for use are established with a rather low level of proof, which needs to be taken into account in the patient management. Methotrexate, mycophenolate, and le- and teri-flunomide, cyclophosphamide, mitoxanthrone are contraindicated if pregnancy is desired due to their teratogenic effects, as well as gonadotoxic effects in the case of cyclophosphamide. Anti-TNF-alpha and mTOR-inhibitors are to be used cautiously if pregnancy is desired, since experience using these drugs is still relatively scarce. Azathioprine, glucocorticoids, mesalazine, anticalcineurins such as cyclosporine and tacrolimus, ß-interferon, glatiramer-acetate and chloroquine can be used during pregnancy, bearing in mind however that side effects may still occur. Experience is limited concerning natalizumab, fingolimod, dimethyl-fumarate and induction treatments. At the time of prescription, patients must be informed of the possible consequences of immunosuppressants on fertility and of the need for contraception. Pregnancy must be planned and the treatment modified if necessary in a pre-conception time period adapted to the half-life of the drug, imperatively in relation with the prescriber of the immunosuppressive drugs.

X Demographics

X Demographics

The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 201 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Russia 1 <1%
Germany 1 <1%
Unknown 199 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 30 15%
Student > Master 23 11%
Other 19 9%
Student > Ph. D. Student 19 9%
Researcher 18 9%
Other 43 21%
Unknown 49 24%
Readers by discipline Count As %
Medicine and Dentistry 75 37%
Pharmacology, Toxicology and Pharmaceutical Science 14 7%
Nursing and Health Professions 13 6%
Biochemistry, Genetics and Molecular Biology 11 5%
Agricultural and Biological Sciences 9 4%
Other 25 12%
Unknown 54 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 53. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 January 2024.
All research outputs
#786,808
of 25,295,968 outputs
Outputs from Orphanet Journal of Rare Diseases
#67
of 3,055 outputs
Outputs of similar age
#11,723
of 290,355 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#2
of 38 outputs
Altmetric has tracked 25,295,968 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,055 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 290,355 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.